News

This placebo controlled, double blind safety extension trial is designed to collect longer-term use patient safety data in support of the company’s submission of a new drug application

The partnership is part of the Stallergenes ‘Enhanced Allergens’ innovation program for a recombinant protein treatment for sublingual desensitisation of allergy to mites. This second-generation treatment is made

Under terms of the non-exclusive licensing arrangement, Hemispherx will receive both royalties as well as income for all Ampligen supplies used in both the ongoing experimental work and

The sNDA is based on efficacy and safety data in more than 670 patients with advanced-stage Parkinson’s disease who were treated with rotigotine in three double-blind, placebo-controlled clinical

In this open label trial, each patient will receive eight weekly infusions of ofatumumab. The first infusion will be 300mg and the seven subsequent infusions will be 1000mg

This recommendation follows the data safety monitoring board’s (DSMB) review of the blinded data from the first one-third of the 830 patients to be enrolled in two ongoing

Alnylam’s Phase I study for ALN-RSV01 was a randomized, double-blind, placebo-controlled trial in healthy adult volunteers to assess the safety, tolerability, and pharmacokinetics of ALN-RSV01 administrated by inhalation

In addition, in an intraperitoneal glucose tolerance test, Sirtris’s SIRT1 activator was shown to control glucose excursion as well as sitagliptin in this pre-clinical model of Type 2

Integra has received 510(k) clearance from the FDA to market flowable wound matrix in the US. Tom Tarca, vice president of marketing for the extremity reconstruction business, Integra,